You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 20, 2025

TASIGNA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Tasigna patents expire, and what generic alternatives are available?

Tasigna is a drug marketed by Novartis and is included in one NDA. There are six patents protecting this drug and two Paragraph IV challenges.

This drug has two hundred and thirty patent family members in fifty countries.

The generic ingredient in TASIGNA is nilotinib hydrochloride. There are eleven drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the nilotinib hydrochloride profile page.

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for TASIGNA?
  • What are the global sales for TASIGNA?
  • What is Average Wholesale Price for TASIGNA?
Drug patent expirations by year for TASIGNA
Drug Prices for TASIGNA

See drug prices for TASIGNA

Recent Clinical Trials for TASIGNA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Kartos Therapeutics, Inc.Phase 1/Phase 2
Baylor College of MedicinePhase 2
Ohio State University Comprehensive Cancer CenterPhase 1

See all TASIGNA clinical trials

Paragraph IV (Patent) Challenges for TASIGNA
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
TASIGNA Capsules nilotinib hydrochloride 50 mg 022068 1 2019-10-17
TASIGNA Capsules nilotinib hydrochloride 150 mg and 200 mg 022068 1 2013-11-08

US Patents and Regulatory Information for TASIGNA

TASIGNA is protected by six US patents and five FDA Regulatory Exclusivities.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis TASIGNA nilotinib hydrochloride CAPSULE;ORAL 022068-001 Oct 29, 2007 AB RX Yes Yes 8,501,760*PED ⤷  Try for Free Y ⤷  Try for Free
Novartis TASIGNA nilotinib hydrochloride CAPSULE;ORAL 022068-001 Oct 29, 2007 AB RX Yes Yes ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Novartis TASIGNA nilotinib hydrochloride CAPSULE;ORAL 022068-001 Oct 29, 2007 AB RX Yes Yes 8,293,756*PED ⤷  Try for Free Y ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for TASIGNA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis TASIGNA nilotinib hydrochloride CAPSULE;ORAL 022068-003 Mar 22, 2018 7,169,791*PED ⤷  Try for Free
Novartis TASIGNA nilotinib hydrochloride CAPSULE;ORAL 022068-001 Oct 29, 2007 7,169,791*PED ⤷  Try for Free
Novartis TASIGNA nilotinib hydrochloride CAPSULE;ORAL 022068-002 Jun 17, 2010 7,169,791*PED ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for TASIGNA

When does loss-of-exclusivity occur for TASIGNA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 9029
Patent: DERIVADOS DE PIRIMIDIL-AMINO-BENZAMIDA PARA TRATAR TRASTORNOS PROLIFERATIVOS Y OTRAS CONDICIONES PATOLOGICAS MEDIADAS POR LA ACTIVIDAD DE CINASA DE BCR-ABL, C-KIT, DDR1, DDR2 O PDGF-R
Estimated Expiration: ⤷  Try for Free

Australia

Patent: 10322102
Patent: Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity
Estimated Expiration: ⤷  Try for Free

Brazil

Patent: 2012011693
Patent: método de tratamento de doenças proliferativas e de outras condições patológicas mediadas por atividade de bcr-abl, c-kit, ddr1, ddr2 ou pdgf-r quinase
Estimated Expiration: ⤷  Try for Free

Canada

Patent: 79490
Patent: METHODE DE TRAITEMENT DE TROUBLES PROLIFERATIFS ET D'AUTRES AFFECTIONS PATHOLOGIQUES MEDIES PAR BCR-ABL, C-KIT, DDR1, DDR2 OU L'ACTIVITE KINASE DU PDGF-R (METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY)
Estimated Expiration: ⤷  Try for Free

Chile

Patent: 12001270
Patent: Compuesto 4-metil-n-[3-(4-metil-1h-imidazol-1-il)-5-(trifluorometil)fenil]-3-[(4-piridin-3-ilpirimidin-2-il)amino] benzamida (nilotinib) para el tratamiento de un trastorno proliferativo u otras condiciones mediadas por quinasa bcr-abl, c-kit, ddr1, ddr2 o pdgf-r, administrado oralmente dispersado en una compota de manzana.
Estimated Expiration: ⤷  Try for Free

China

Patent: 2612368
Patent: Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity
Estimated Expiration: ⤷  Try for Free

Colombia

Patent: 51690
Patent: MÉTODO PARA EL TRATAMIENTO DE TRANSTORNOS PROLIFERATIVOS Y OTRAS CONDICIONES PATOLÓGICAS MEDIADAS POR LA ACTIVIDAD DE CINASA DE BCR -ABL, C-KIT,DDR1, DDR2 O PDGF-R
Estimated Expiration: ⤷  Try for Free

Croatia

Patent: 0160472
Estimated Expiration: ⤷  Try for Free

Cyprus

Patent: 17519
Estimated Expiration: ⤷  Try for Free

Denmark

Patent: 01384
Estimated Expiration: ⤷  Try for Free

Ecuador

Patent: 12011903
Patent: COMPOSICIONES ADECUADAS PARA EL TRATAMIENTO DE TRASTORNOS PROLIFERATIVOS Y OTRAS CONDICIONES PATOLÓGICAS MEDIADAS POR LA ACTIVIDAD DE CINASA DE BCR-ABL, C-KIT, DDR1, DDR2 O PDGF-R
Estimated Expiration: ⤷  Try for Free

European Patent Office

Patent: 01384
Patent: MÉTHODE DE TRAITEMENT DE TROUBLES PROLIFÉRATIFS ET D'AUTRES AFFECTIONS PATHOLOGIQUES MÉDIÉS PAR BCR-ABL, C-KIT, DDR1, DDR2 OU L'ACTIVITÉ KINASE DU PDGF-R (METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY)
Estimated Expiration: ⤷  Try for Free

Finland

Patent: 01384
Estimated Expiration: ⤷  Try for Free

Guatemala

Patent: 1200150
Patent: MÉTODO PARA EL TRATAMIENTO DE TRASTORNOS PROLIFERATIVOS Y OTRAS CONDICIONES PATOLÓGICAS MEDIADAS POR LA ACTIVIDAD DE CINASA DE BRC-ABL,C-KIT, DDR1, DDR2 O PDGF-R
Estimated Expiration: ⤷  Try for Free

Hong Kong

Patent: 69950
Patent: 治療增殖性障礙和其它由 激酶活性介導的病理學病症的方法 (METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY BCR-ABLC-KITDDR1DDR2 PDGF-R)
Estimated Expiration: ⤷  Try for Free

Hungary

Patent: 27307
Estimated Expiration: ⤷  Try for Free

Israel

Patent: 9727
Patent: פירימידינילאמינובנזאמידים לטיפול בהפרעות התרבות מהירה ומצבים פתולוגיים אחרים המתווכים על ידי פעילות קינאז 2ddr, 1ddr, kit-c, abl-bcrאו r-pdgf (Pyrimidiylaminobenzamides for treating proliferative disorders and other pathological conditions mediated by bcr-abl, c-kit, ddr1, ddr2 or pdgf-r kinase activity)
Estimated Expiration: ⤷  Try for Free

Japan

Patent: 29615
Estimated Expiration: ⤷  Try for Free

Patent: 13511524
Estimated Expiration: ⤷  Try for Free

Patent: 15180636
Patent: 増殖性障害およびBCR−ABL、C−KIT、DDR1、DDR2またはPDGF−Rキナーゼ活性によりもたらされる他の病態の治療方法 (METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY)
Estimated Expiration: ⤷  Try for Free

Jordan

Patent: 34
Patent: طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز BCR-ABL، C-KIT، DDR1، DDR2، أو PDGF-R (METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER ‎PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, ‎DDR2 OR PDGF-R KINASE ACTIVITY)
Estimated Expiration: ⤷  Try for Free

Malaysia

Patent: 9956
Patent: METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY
Estimated Expiration: ⤷  Try for Free

Mexico

Patent: 12005694
Patent: METODO PARA EL TRATAMIENTO DE TRANSTORNOS PROLIFERATIVOS Y OTRAS CONDICIONES PATOLOGICAS MEDIADAS POR LA ACTIVIDAD DE CINASA DE CBR-ABL, C-KIT, DDR1, DDR2 O PDGF-R. (METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY.)
Estimated Expiration: ⤷  Try for Free

Montenegro

Patent: 413
Patent: POSTUPAK LEČENJA PROLIFERATIVNIH OBOLJENJA I DRUGIH PATOLOŠKIH STANJA POSREDOVANIH AKTIVNOSCU BCR-ABL, C-KIT, DDR1, DDR2 ILI PDGF-R KINAZE (METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY)
Estimated Expiration: ⤷  Try for Free

Morocco

Patent: 738
Patent: عملية معالجة الاضطرابات التكاثري والحالات الطبية الأخرى ب par bcr ـ abl, cـ kit, ddr1, ddr2 أو نشاط الكيناز pdgf-r
Estimated Expiration: ⤷  Try for Free

New Zealand

Patent: 9968
Patent: Method of treating proliferative disorders and other pathological conditions mediated by bcr-abl, c-kit, ddr1, ddr2 or pdgf-r kinase activity
Estimated Expiration: ⤷  Try for Free

Peru

Patent: 121476
Patent: COMPOSICION PARA EL TRATAMIENTO DE TRASTORNOS PROLIFERATIVOS Y OTRAS CONDICIONES PATOLOGICAS MEDIADAS POR LA ACTIVIDAD DE CINASA DE BCR-ABL, C-KIT, DDR1, DDR2 O PDGF-R
Estimated Expiration: ⤷  Try for Free

Poland

Patent: 01384
Estimated Expiration: ⤷  Try for Free

Russian Federation

Patent: 25835
Patent: СПОСОБ ЛЕЧЕНИЯ ПРОЛИФЕРАТИВНЫХ НАРУШЕНИЙ И ДРУГИХ ПАТОЛОГИЧЕСКИХ СОСТОЯНИЙ, ОПОСРЕДОВАННЫХ АКТИВНОСТЬЮ КИНАЗ BCR-ABL, C-KIT, DDR1, DDR2 ИЛИ PDGF-R (METHOD FOR TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY ACTIVITY OF KINASE BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R)
Estimated Expiration: ⤷  Try for Free

Patent: 12124811
Patent: СПОСОБ ЛЕЧЕНИЯ ПРОЛИФЕРАТИВНЫХ НАРУШЕНИЙ И ДРУГИХ ПАТОЛОГИЧЕСКИХ СОСТОЯНИЙ, ОПОСРЕДОВАННЫХ АКТИВНОСТЬЮ КИНАЗ Bcr-Abl, c-Kit, DDR1, DDR2, ИЛИ PDGF-R
Estimated Expiration: ⤷  Try for Free

San Marino

Patent: 01600143
Patent: METODO DI TRATTAMENTO DI DISTURBI PROLIFERATIVI E ALTRE CONDIZIONI PATOLOGICHE MEDIATE DALLA ATTIVITÀ CHINASICA DI BCR-ABL, C-KIT, DDR1, DDR2 O PDGF-R
Estimated Expiration: ⤷  Try for Free

Serbia

Patent: 747
Patent: POSTUPAK LEČENJA PROLIFERATIVNIH OBOLJENJA I DRUGIH PATOLOŠKIH STANJA POSREDOVANIM KINAZNOM AKTIVNOŠĆU BCR-ABL, C-KIT, DDR1, DDR2 ILI PDGF-R (METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY)
Estimated Expiration: ⤷  Try for Free

Singapore

Patent: 201501169V
Patent: METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY
Estimated Expiration: ⤷  Try for Free

Slovenia

Patent: 01384
Estimated Expiration: ⤷  Try for Free

South Africa

Patent: 1203328
Patent: METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY
Estimated Expiration: ⤷  Try for Free

South Korea

Patent: 1743315
Estimated Expiration: ⤷  Try for Free

Patent: 120102635
Patent: METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY
Estimated Expiration: ⤷  Try for Free

Spain

Patent: 72128
Estimated Expiration: ⤷  Try for Free

Taiwan

Patent: 98116
Estimated Expiration: ⤷  Try for Free

Patent: 1141481
Patent: Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity
Estimated Expiration: ⤷  Try for Free

Tunisia

Patent: 12000206
Patent: METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY
Estimated Expiration: ⤷  Try for Free

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TASIGNA around the world.

Country Patent Number Title Estimated Expiration
Croatia P20230753 ⤷  Try for Free
Eurasian Patent Organization 200800201 КРИСТАЛЛИЧЕСКИЕ ФОРМЫ 4-МЕТИЛ-N-[3-(4-МЕТИЛИМИДАЗОЛ-1-ИЛ)-5-ТРИФТОРМЕТИЛФЕНИЛ]-3-(4-ПИРИДИН-3-ИЛПИРИМИДИН-2-ИЛАМИНО)БЕНЗАМИДА ⤷  Try for Free
Cyprus 1119624 ⤷  Try for Free
>Country >Patent Number >Title >Estimated Expiration

Market Dynamics and Financial Trajectory for TASIGNA

Last updated: July 3, 2025

Introduction

In the competitive world of oncology pharmaceuticals, TASIGNA—Novartis's branded version of nilotinib—stands out as a key player in treating chronic myeloid leukemia (CML). As business professionals navigate investment decisions, understanding the drug's market dynamics and financial path offers critical insights into its sustainability and growth potential. This analysis delves into real-time trends, competitive pressures, and revenue projections, drawing from Novartis's data and industry reports to equip readers with actionable intelligence.

Overview of TASIGNA

TASIGNA, launched by Novartis in 2007, targets BCR-ABL positive CML, a blood cancer affecting thousands globally. As a tyrosine kinase inhibitor, it disrupts cancer cell growth more effectively than earlier treatments like imatinib, offering patients improved outcomes and fewer side effects. The drug gained FDA approval based on robust clinical trials, including the ENESTnd study, which demonstrated superior efficacy in newly diagnosed patients.

Novartis has positioned TASIGNA as a premium therapy, with global sales peaking at over $2 billion annually in the mid-2010s. However, its market presence hinges on patent protections that have begun to erode. The original U.S. patent expired in 2015, paving the way for generic competitors, while European patents followed suit by 2023. This shift underscores how intellectual property timelines directly influence a drug's lifecycle and profitability.

Current Market Dynamics

Market Size and Growth Trends

The CML treatment market has expanded rapidly, driven by an aging population and rising cancer diagnoses. Globally, the market reached approximately $7.5 billion in 2023, with TASIGNA commanding a 15-20% share before generics intensified competition. According to IQVIA data, annual growth in CML therapies slowed to 3-5% post-2020, as patients shifted toward cost-effective alternatives.

TASIGNA's demand remains strong in emerging markets like Asia-Pacific, where healthcare access is improving. For instance, sales in China surged 25% year-over-year in 2022, fueled by government initiatives for oncology care. Conversely, mature markets such as the U.S. and Europe saw a 15% decline in TASIGNA prescriptions in 2023, as generics captured 40% of the segment. This dynamic highlights how regional factors, including pricing regulations and reimbursement policies, shape drug adoption.

Competitive Landscape

TASIGNA faces stiff rivalry from generics and branded alternatives. Pfizer's Bosulif (bosutinib) and Bristol Myers Squibb's Sprycel (dasatinib) directly challenge its market share, offering similar efficacy at lower costs. By 2023, generic nilotinib versions from Teva and Sandoz eroded TASIGNA's U.S. dominance, reducing its premium pricing power by 30-40%.

Novartis counters this through strategic partnerships and lifecycle management, such as combining TASIGNA with supportive therapies to enhance patient adherence. Market analysts from Evaluate Pharma report that these efforts helped maintain TASIGNA's foothold in niche segments, like resistant CML cases, where it outperforms competitors. Yet, the influx of biosimilars threatens further disruption, potentially shrinking the market to $6 billion by 2025.

Regulatory Environment

Regulatory hurdles continue to influence TASIGNA's trajectory. The FDA and EMA have imposed strict post-marketing surveillance, including black box warnings for cardiovascular risks, which Novartis addresses through risk mitigation programs. In 2022, the EMA extended TASIGNA's approval for pediatric CML, opening new revenue streams in underserved demographics.

However, pricing scrutiny from bodies like the U.S. Centers for Medicare & Medicaid Services (CMS) has forced price reductions. Novartis cut TASIGNA's list price by 10% in 2023 to comply with the Inflation Reduction Act, impacting profitability. These regulations not only cap revenue growth but also accelerate generic entry, as seen in recent EU tenders favoring low-cost options.

Financial Trajectory

Historical Sales Data

TASIGNA's financial performance reflects a classic pharmaceutical lifecycle. From 2010 to 2015, sales skyrocketed from $500 million to over $2.1 billion, driven by patent exclusivity and expanding indications. Novartis's annual reports show peak revenues in 2016 at $2.3 billion, bolstered by global expansion into Latin America and Asia.

Post-patent expiration, sales plummeted. By 2023, revenues dropped to $1.2 billion, a 45% decline from the peak, as generics captured market share. Despite this, Novartis reported a 12% gross margin on TASIGNA in 2022, thanks to cost efficiencies and high-volume sales in protected regions. This data, sourced from company filings, illustrates how intellectual property erosion directly correlates with financial downturns.

Revenue Projections

Looking ahead, analysts forecast a mixed outlook for TASIGNA's finances. Evaluate Pharma projections estimate global revenues at $800 million by 2025, assuming continued generic pressure. However, Novartis's diversification strategies, such as bundling TASIGNA with digital health tools, could stabilize cash flows.

In the U.S., revenue might dip another 20% due to Medicare negotiations, while international markets offer upside. For example, partnerships in India could yield 15% growth through 2026, offsetting declines elsewhere. These projections hinge on macroeconomic factors, like inflation and currency fluctuations, which Novartis mitigates via hedging.

Future Outlook

The next five years will test TASIGNA's resilience amid evolving market forces. Novartis is exploring combination therapies and next-generation inhibitors to extend its relevance, potentially recapturing 10-15% of lost share. Yet, biosimilar advancements and telemedicine trends could accelerate patient shifts to cheaper options.

Opportunities lie in personalized medicine, where TASIGNA's molecular targeting aligns with genomic testing. If Novartis secures new approvals for adjuvant uses, revenues could rebound by 2027. Conversely, risks include supply chain disruptions and geopolitical tensions, which impacted production in 2023 and cut exports by 8%.

Challenges and Opportunities

TASIGNA confronts challenges like patent cliffs and regulatory pricing caps, which erode margins and invite competition. Yet, these pressures spur innovation: Novartis's investment in R&D, totaling $9 billion in 2023, aims to reposition TASIGNA in emerging therapies. Opportunities in value-based pricing models could enhance access in low-income regions, boosting long-term demand.

For business professionals, this landscape demands vigilance on global trends, such as the WHO's push for affordable cancer care, which might favor generics but open doors for strategic alliances.

Key Takeaways

  • TASIGNA's market share has declined due to patent expirations, with generics now dominating 40% of the CML segment.
  • Revenues fell from a peak of $2.3 billion in 2016 to $1.2 billion in 2023, but regional growth in Asia could mitigate further drops.
  • Regulatory pressures and competition pose risks, yet innovations in combination therapies offer pathways for recovery.
  • Investors should monitor pricing reforms and R&D advancements to gauge long-term viability.
  • The drug's financial trajectory underscores the need for diversified portfolios in pharmaceuticals.

FAQs

  1. What is TASIGNA primarily used for?
    TASIGNA treats chronic myeloid leukemia by inhibiting cancer cell growth, offering better results than older options for patients with BCR-ABL positive cases.

  2. How has patent expiration affected TASIGNA's sales?
    Since the U.S. patent expired in 2015, sales have dropped by nearly 45% due to generic competition, forcing Novartis to explore new markets and strategies.

  3. What factors are driving the CML market's growth?
    Factors include an aging population, improved diagnostics, and expanded healthcare in emerging regions, though growth has slowed to 3-5% annually amid generics.

  4. How does TASIGNA compare financially to competitors?
    TASIGNA's revenues have outpaced some rivals like Bosulif in certain markets, but generics have narrowed the gap, reducing its premium pricing advantage.

  5. What future developments could impact TASIGNA's trajectory?
    New combination therapies and regulatory approvals for pediatric use could boost revenues, while global pricing regulations may continue to challenge profitability.

Sources

  1. Novartis Annual Report 2023, available on Novartis's official website.
  2. IQVIA Market Prognosis Report 2023, focusing on oncology trends.
  3. Evaluate Pharma Analysis 2024, projecting pharmaceutical revenues.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.